These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 24993163)

  • 41. High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: Clinicopathological significance and correlation with epithelial-mesenchymal transition.
    Oh KY; Cho SD; Yoon HJ; Lee JI; Ahn SH; Hong SD
    J Oral Pathol Med; 2019 May; 48(5):413-420. PubMed ID: 30889301
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
    Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
    Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BRAF p.V600E mutations are not unique to ameloblastoma and are shared by other odontogenic tumors with ameloblastic morphology.
    Brunner P; Bihl M; Jundt G; Baumhoer D; Hoeller S
    Oral Oncol; 2015 Oct; 51(10):e77-8. PubMed ID: 26306423
    [No Abstract]   [Full Text] [Related]  

  • 44. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
    Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P
    Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
    Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
    Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adenoid ameloblastoma with dentinoid is molecularly different from ameloblastomas and adenomatoid odontogenic tumors.
    Coura BP; Dos Santos JN; Fonseca FP; Bernardes VF; de Aquino SN; Jorge Júnior J; Vargas PA; Romañach MJ; de Andrade BAB; Gomez RS; Gomes CC
    J Oral Pathol Med; 2021 Nov; 50(10):1067-1071. PubMed ID: 34549835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High frequency of BRAF V600E mutation in Iranian population ameloblastomas.
    Derakhshan S; Aminishakib P; Karimi A; Saffar H; Abdollahi A; Mohammadpour H; Kharazi Fard MJ; Memarha A
    Med Oral Patol Oral Cir Bucal; 2020 Jul; 25(4):e502-e507. PubMed ID: 32388526
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.
    Méhes G; Irsai G; Bedekovics J; Beke L; Fazakas F; Rózsa T; Kiss C
    Am J Surg Pathol; 2014 Dec; 38(12):1644-8. PubMed ID: 25118810
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of BRAF V600E mutation in odontogenic tumors by high-performance MALDI-TOF analysis.
    Togni L; Zizzi A; Mazzucchelli R; Santarelli A; Rubini C; Mascitti M
    Int J Oral Sci; 2022 Apr; 14(1):22. PubMed ID: 35468886
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
    Tran G; Huynh TN; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.
    Pohl G; Ho CL; Kurman RJ; Bristow R; Wang TL; Shih IeM
    Cancer Res; 2005 Mar; 65(5):1994-2000. PubMed ID: 15753399
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
    Burger M; Denzinger S; Hammerschmied C; Tannapfel A; Maderstorfer A; Wieland WF; Hartmann A; Stoehr R
    Eur Urol; 2006 Nov; 50(5):1102-9; discussion 1109-10. PubMed ID: 16413100
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progress towards personalized medicine for ameloblastoma.
    Gomes CC; Diniz MG; Gomez RS
    J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies.
    Nguyen J; Saffari PS; Pollack AS; Vennam S; Gong X; West RB; Pollack JR
    J Dent Res; 2022 Nov; 101(12):1517-1525. PubMed ID: 35689405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ultra-frequent HRAS p.Q61R somatic mutation in canine acanthomatous ameloblastoma reveals pathogenic similarities with human ameloblastoma.
    Peralta S; McCleary-Wheeler AL; Duhamel GE; Heikinheimo K; Grenier JK
    Vet Comp Oncol; 2019 Sep; 17(3):439-445. PubMed ID: 31041834
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutational Signatures in Mandibular Ameloblastoma Correlate with Smoking.
    Guan P; Wong SF; Lim JQ; Ng CCY; Soong PL; Sim CQX; Ong CK; Rajasegaran V; Myint SS; Lee JY; Tan HK; Iyer NG; Soo KC; Teh BT; Tay ABG
    J Dent Res; 2019 Jun; 98(6):652-658. PubMed ID: 30917298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BRAF p.V600E status in epithelial areas of ameloblastoma with different histological aspects: Implications to the clinical practice.
    Sant'Ana MSP; Dos Santos Costa SF; da Silva MP; Martins-Chaves RR; Pereira TDSF; de Oliveira EM; Martínez Pedraza R; de Castro WH; Gomes CC; Gomez RS; Fonseca FP
    J Oral Pathol Med; 2021 May; 50(5):478-484. PubMed ID: 33377543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic strategies for inhibiting oncogenic BRAF signaling.
    Halilovic E; Solit DB
    Curr Opin Pharmacol; 2008 Aug; 8(4):419-26. PubMed ID: 18644254
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The genetic landscape of ganglioglioma.
    Pekmezci M; Villanueva-Meyer JE; Goode B; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Chamyan G; Maher OM; Khatib Z; Kleinschmidt-DeMasters BK; Samuel D; Mueller S; Banerjee A; Clarke JL; Cooney T; Torkildson J; Gupta N; Theodosopoulos P; Chang EF; Berger M; Bollen AW; Perry A; Tihan T; Solomon DA
    Acta Neuropathol Commun; 2018 Jun; 6(1):47. PubMed ID: 29880043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.